Neuland Laboratories Limited (NEULANDLAB) Operating Income 2023–2026

Name: Neuland Laboratories Limited (NEULANDLAB) operating income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Neuland Laboratories Limited annual operating income for fiscal 2026 was ₹4.9 billion, an increase of 83.8% from ₹2.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

NEULANDLAB Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Operating Income (EBIT)	₹4.9B	₹2.7B	₹4.1B	₹2.3B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NEULANDLAB Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Operating Income (EBIT)	₹2.0B	₹2.8B	₹532M	₹1.3B	₹143M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

AJANTPHARM Operating Income — Ajanta Pharma Limited
EMCURE Operating Income — Emcure Pharmaceuticals Limited
WOCKPHARMA Operating Income — Wockhardt Limited
1276 Operating Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
4540 Operating Income — Tsumura & Co.
PPLPHARMA Operating Income — Piramal Pharma Limited

More NEULANDLAB metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All NEULANDLAB financial statements → Interactive NEULANDLAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.